 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 March 1999 | Volume 130 Issue 5 | Pages 389-396
Background: Compared with other insulin regimens, combination therapy with oral hypoglycemic agents and bedtime insulin produces similar improvement in glycemic control but induces less weight gain.
Objective: To determine whether bedtime insulin regimens differ with respect to their effects on weight gain in patients with type 2 diabetes.
Design: Randomized, controlled trial.
Setting: Four outpatient clinics at central hospitals.
Patients: 96 patients (mean age, 58 ± 1 years; mean body mass index, 29 ± 1 kg/m2) whose type 2 diabetes was poorly controlled with sulfonylurea therapy (mean glycosylated hemoglobin value, 9.9% ± 0.2%; mean fasting plasma glucose level, 11.9 ± 0.3 mmol/L [214 ± 5 mg/dL]).
Intervention: Random assignment to 1 year of treatment with bedtime intermediate-acting insulin plus glyburide (10.5 mg) and placebo, metformin (2 g) and placebo, glyburide and metformin, or a second injection of intermediate-acting insulin in the morning. Patients were taught to adjust the bedtime insulin dose on the basis of fasting glucose measurements.
Measurements: Body weight, biochemical and symptomatic hypoglycemias, and indices of glycemic control.
Results: At 1 year, body weight remained unchanged in patients receiving bedtime insulin plus metformin (mean change, 0.9 ± 1.2 kg; P < 0.001 compared with all other groups) but increased by 3.9 ± 0.7 kg, 3.6 ± 1.2 kg, and 4.6 ± 1.0 kg in patients receiving bedtime insulin plus glyburide, those receiving bedtime insulin plus both oral drugs, and those receiving bedtime and morning insulin, respectively. The greatest decrease in the glycosylated hemoglobin value was observed in the bedtime insulin and metformin group (from 9.7% ± 0.4% to 7.2% ± 0.2% [difference, –2.5 ± 0.4 percentage points] at 1 year; P < 0.001 compared with 0 months and P < 0.05 compared with other groups). This group also had significantly fewer symptomatic and biochemical cases of hypoglycemia (P < 0.05) than the other groups.
Conclusions: Combination therapy with bedtime insulin plus metformin prevents weight gain. This regimen also seems superior to other bedtime insulin regimens with respect to improvement in glycemic control and frequency of hypoglycemia.
Author and Article Information
From University of Helsinki, Helsinki; Kymenlaakso Central Hospital, Kotka; Jorvi Hospital and Orion, Espoo; Lapland Central Hospital, Rovaniemi; and South Carelian Central Hospital, Lappeenranta, Finland.
Grant Support: By the Academy of Finland (Dr. Yki-Järvinen). Antidiabetic drugs, including placebo tablets, were prepared by Orion, Espoo, Finland.
Acknowledgments: The authors thank nurses Liisa Hyvärinen, Raija Härkönen, Leena Pekkonen, and Mare Riihelä for their help, patience, and educational skills. They also thank Kikka Runeberg, Sari Hämäläinen, and Kati Tuomola for technical assistance.
Requests for Reprints: Hannele Yki-Järvinen, MD, Department of Medicine, University of Helsinki, Haartmaninkatu 4, Box 340, FIN-00029 HUCH, Helsinki, Finland.
Current Author Addresses: Dr. Yki-Järvinen: Department of Medicine, University of Helsinki, Haartmaninkatu 4, Box 340, FIN-00029 HUCH, Helsinki, Finland.
Dr. Ryysy: Kymenlaakso Central Hospital, FIN-48210 Kotka, Finland.
Dr. Nikkilä: Jorvi Hospital, Turuntie 150, FIN-02740 Espoo, Finland.
Dr. Tulokas: Lapland Central Hospital, Box 8041, FIN-96101 Rovaniemi, Finland.
Dr. Vanamo: South Carelian Central Hospital, Valto Käkelän katu, FIN-53130 Lappeenranta, Finland.
Ms. Heikkilä: Orion, Box 65, FIN-02101 Espoo, Finland. ARTICLE
Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus
A Randomized, Controlled Trial
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  C. Stettler, M. Stahl, S. Allemann, P. Diem, K. Schmidlin, M. Zwahlen, W. Riesen, U. Keller, and E. Christ Association of 1,5-Anhydroglucitol and 2-h Postprandial Blood Glucose in Type 2 Diabetic Patients Diabetes Care, August 1, 2008; 31(8): 1534 - 1535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Diabetes and Obesity: Part 2 Diabetes Care, January 1, 2008; 31(1): 176 - 182. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Juurinen, A. Kotronen, M. Graner, and H. Yki-Jarvinen Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 118 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. McMahon and R. G. Dluhy Intention to Treat -- Initiating Insulin and the 4-T Study N. Engl. J. Med., October 25, 2007; 357(17): 1759 - 1761. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Exploring Treatment Strategies for Type 2 Diabetes Diabetes Care, October 1, 2007; 30(10): 2737 - 2745. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Blonde Easing the Transition to Insulin Therapy in People With Type 2 Diabetes The Diabetes Educator, July 1, 2007; 33(Supplement_7): 232S - 240S. [Full Text] [PDF]
|
|
|
|
|
|
H. Yki-Jarvinen, L. Juurinen, M. Alvarsson, T. Bystedt, I. Caldwell, M. Davies, S. Lahdenpera, G. Nijpels, and M. Vahatalo Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups Diabetes Care, June 1, 2007; 30(6): 1364 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan and On Behalf of the ADA/DASD Consensus Group Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Cryer, Porta and Trento, and Parkin and Davidson Diabetes Care, January 1, 2007; 30(1): 194 - 196. [Full Text] [PDF]
|
|
|
|
|
|
C. Triplitt, L. Glass, Y. Miyazaki, E. Wajcberg, A. Gastaldelli, E. De Filippis, E. Cersosimo, and R. A. DeFronzo Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care, November 1, 2006; 29(11): 2371 - 2377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, and B. Zinman Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, August 1, 2006; 29(8): 1963 - 1972. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Murphy and S. Dinneen Inhaled insulin added onto or replacing 2 oral agents reduced haemoglobin A1c concentrations in type 2 diabetes Evid. Based Med., June 1, 2006; 11(3): 77 - 77. [Full Text] [PDF]
|
|
|
|
|
|
S. N. Davis and S. M. Renda Psychological Insulin Resistance: Overcoming Barriers to Starting Insulin Therapy. The Diabetes Educator, June 1, 2006; 32(Supplement_4): 146S - 152S. [Full Text] [PDF]
|
|
|
|
|
|
L. Kennedy, W. H. Herman, P. Strange, A. Harris, and for the GOAL A1C Team Impact of Active Versus Usual Algorithmic Titration of Basal Insulin and Point-of-Care Versus Laboratory Measurement of HbA1c on Glycemic Control in Patients With Type 2 Diabetes: The Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial Diabetes Care, January 1, 2006; 29(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Davies, F. Storms, S. Shutler, M. Bianchi-Biscay, R. Gomis, and for the AT.LANTUS Study Group Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine Diabetes Care, June 1, 2005; 28(6): 1282 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Bethel and M. N. Feinglos Basal Insulin Therapy in Type 2 Diabetes J Am Board Fam Med, May 1, 2005; 18(3): 199 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J Hendra Review: Diabetes and insulin therapy in older people The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1): 19 - 23. [Abstract] [PDF]
|
|
|
|
|
|
J. Burke Review: Combination treatment with insulin and oral agents in type 2 diabetes mellitus The British Journal of Diabetes & Vascular Disease, March 1, 2004; 4(2): 71 - 76. [Abstract] [PDF]
|
|
|
|
 |
|
 K. K. Daugherty Review of Insulin Therapy Journal of Pharmacy Practice, February 1, 2004; 17(1): 10 - 19. [Abstract] [PDF]
|
|
|
|
 |
|
 S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Riddle, J. Rosenstock, and J. Gerich The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care, November 1, 2003; 26(11): 3080 - 3086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Sheehan Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach Clin. Med. Res., July 1, 2003; 1(3): 189 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fritsche, M. A. Schweitzer, H.-U. Haring, and the 4001 Study Group* Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes: A Randomized, Controlled Trial Ann Intern Med, June 17, 2003; 138(12): 952 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. DeWitt and D. C. Dugdale Using New Insulin Strategies in the Outpatient Treatment of Diabetes: Clinical Applications JAMA, May 7, 2003; 289(17): 2265 - 2269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. White Jr., S. N. Davis, R. Cooppan, M. B. Davidson, K. Mulcahy, G. A. Manko, and D. Nelinson Clarifying the Role of Insulin in Type 2 Diabetes Management Clin. Diabetes, January 1, 2003; 21(1): 14 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Wulffele, A. Kooy, P. Lehert, D. Bets, J. C. Ogterop, B. Borger van der Burg, A. J.M. Donker, and C. D.A. Stehouwer Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes Diabetes Care, December 1, 2002; 25(12): 2133 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan Initial Management of Glycemia in Type 2 Diabetes Mellitus N. Engl. J. Med., October 24, 2002; 347(17): 1342 - 1349. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Furlong, S. A. Hulme, S. V. O'Brien, and K. J. Hardy Repaglinide Versus Metformin in Combination With Bedtime NPH Insulin in Patients With Type 2 Diabetes Established on Insulin/Metformin Combination Therapy Diabetes Care, October 1, 2002; 25(10): 1685 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Treatment of Type 2 Diabetes: The American Association of Clinical Endocrinologists Meeting, May 2002 Diabetes Care, September 1, 2002; 25(9): 1644 - 1649. [Full Text] [PDF]
|
|
|
|
|
|
B. Fruehwald-Schultes, W. Kern, K. M. Oltmanns, S. Sopke, B. Toschek, J. Born, H. L. Fehm, and A. Peters Metformin Does Not Adversely Affect Hormonal and Symptomatic Responses to Recurrent Hypoglycemia J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4187 - 4192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yki-Järvinen Combination Therapies With Insulin in Type 2 Diabetes Diabetes Care, April 1, 2001; 24(4): 758 - 767. [Full Text]
|
|
|
|
|
|
L. Ryysy and H. Yki-Järvinen Improvement of Glycemic Control by 1 Year of Insulin Therapy Leads to a Sustained Decrease in sE-Selectin Concentrations in Type 2 Diabetes Diabetes Care, March 1, 2001; 24(3): 549 - 554. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. Nathan Inhaled Insulin for Type 2 Diabetes: Solution or Distraction? Ann Intern Med, February 6, 2001; 134(3): 242 - 244. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Vehkavaara, S. Makimattila, A. Schlenzka, J. Vakkilainen, J. Westerbacka, and H. Yki-Jarvinen Insulin Therapy Improves Endothelial Function in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 545 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Reducing long-term complications of type 2 diabetes DTB, November 1, 1999; 37(11): 84 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Other Articles Noted Evid. Based Nurs., October 1, 1999; 2(4): 105 - 112. [Full Text]
|
|
|
|
|
|
R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Insulin and Metformin for Type 2 Diabetes Journal Watch (General), March 19, 1999; 1999(319): 1 - 1. [Full Text]
|
|
|
|
|
|
D. M. Nathan Treating Type 2 Diabetes with Respect Ann Intern Med, March 2, 1999; 130(5): 440 - 441. [Full Text] [PDF]
|
|
Article
